Logo image of NIVF

NEWGENIVF GROUP LTD-A (NIVF) Stock Fundamental Analysis

NASDAQ:NIVF - Nasdaq - VGG0544E2042 - Common Stock - Currency: USD

0.52  -0.03 (-5.11%)

After market: 0.5182 0 (-0.35%)

Fundamental Rating

0

NIVF gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 103 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of NIVF have multiple concerns. NIVF is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NIVF had negative earnings in the past year.
In the past year NIVF has reported a negative cash flow from operations.
NIVF Yearly Net Income VS EBIT VS OCF VS FCFNIVF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -1M -2M

1.2 Ratios

NIVF has a worse Return On Assets (-3.22%) than 62.14% of its industry peers.
NIVF has a Return On Equity of -4.40%. This is comparable to the rest of the industry: NIVF outperforms 45.63% of its industry peers.
Industry RankSector Rank
ROA -3.22%
ROE -4.4%
ROIC N/A
ROA(3y)-0.84%
ROA(5y)N/A
ROE(3y)-1.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NIVF Yearly ROA, ROE, ROICNIVF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -2 -4 -6 -8

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NIVF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NIVF Yearly Profit, Operating, Gross MarginsNIVF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for NIVF has been reduced compared to 1 year ago.
NIVF has a worse debt/assets ratio than last year.
NIVF Yearly Shares OutstandingNIVF Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10K 20K 30K 40K
NIVF Yearly Total Debt VS Total AssetsNIVF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M

2.2 Solvency

NIVF has an Altman-Z score of -0.65. This is a bad value and indicates that NIVF is not financially healthy and even has some risk of bankruptcy.
NIVF has a Altman-Z score of -0.65. This is amonst the worse of the industry: NIVF underperforms 81.55% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that NIVF is not too dependend on debt financing.
NIVF has a Debt to Equity ratio of 0.10. This is in the better half of the industry: NIVF outperforms 72.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -0.65
ROIC/WACCN/A
WACCN/A
NIVF Yearly LT Debt VS Equity VS FCFNIVF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M 60M

2.3 Liquidity

NIVF has a Current Ratio of 0.02. This is a bad value and indicates that NIVF is not financially healthy enough and could expect problems in meeting its short term obligations.
NIVF's Current ratio of 0.02 is on the low side compared to the rest of the industry. NIVF is outperformed by 97.09% of its industry peers.
A Quick Ratio of 0.02 indicates that NIVF may have some problems paying its short term obligations.
The Quick ratio of NIVF (0.02) is worse than 97.09% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
NIVF Yearly Current Assets VS Current LiabilitesNIVF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 500K 1M 1.5M 2M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for NIVF have decreased strongly by -300.50% in the last year.
EPS 1Y (TTM)-300.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-357.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NIVF. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NIVF Price Earnings VS Forward Price EarningsNIVF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NIVF Per share dataNIVF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NIVF!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEWGENIVF GROUP LTD-A

NASDAQ:NIVF (7/25/2025, 8:10:54 PM)

After market: 0.5182 0 (-0.35%)

0.52

-0.03 (-5.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners2.28%
Inst Owner Change0%
Ins Owners2.26%
Ins Owner Change0%
Market Cap2.25M
AnalystsN/A
Price TargetN/A
Short Float %5.62%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-39.78
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS3.61
TBVpS3.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.22%
ROE -4.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-0.84%
ROA(5y)N/A
ROE(3y)-1.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -0.65
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-300.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-357.44%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-395.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.77%
OCF growth 3YN/A
OCF growth 5YN/A